الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 85 |  |  |
| | | from | 85 | | |
Abstract
Chemotherapy induced peripheral neuropathy (CIPN) remains one of the major doselimiting factors in oncology. Around 30–40% of patients undergoing chemotherapy develop peripheral neuropathy. According to National Cancer Institute (NCI), CIPN is one of the major reasons responsible for cessation of treatment, and hence is responsible for decreased chemotherapeutic efficacy and higher relapses.
This situation forms a challenge for oncologists as, during the chemotherapy treatment course, no signs can indicate the level of patient affection to reduce chemotherapy drug dosage to decrease CIPN symptoms.
The incidence of CIPN caused by taxanes may be very elevated and ranges from 11 to 87%, with the highest rates related to paclitaxel, the mechanisms of neurotoxicity of taxanes are multifactorial.
Although several studies were conducted to provide a protective agent against CIPN, ASCO still doesn’t recommend any prophylactic treatment against CIPN outside clinical trials
The present study included 30 female patients have breast cancer receiving adjuvant weekly paclitaxel for 12 cycles were allowed to use hypothermic gloves on one hand 15min before, during, and 15min after weekly Paclitaxel d